A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

PURPOSE: Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-base DNA oligonucleotide called PNT100. METHODS: Patients with malignant solid tumors were assigned sequentially to one of te...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909249/
https://www.ncbi.nlm.nih.gov/pubmed/24297683
http://dx.doi.org/10.1007/s00280-013-2361-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909249/
https://www.ncbi.nlm.nih.gov/pubmed/24297683
http://dx.doi.org/10.1007/s00280-013-2361-0

Ejemplares similares